Establishment of a cost-effective method to detect FLT-ITD and D835 mutations in acute myeloid leukemia patients in the Taiwanese population
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pokharel, 2012, Leukemia: a review article, Int J Adv Res Pharm Bio Sci, 2, 397
Sacha, 2014, Imatinib in chronic myeloid leukemia: an overview, Mediterr J Hematol Infect Dis, 6, e2014007, 10.4084/mjhid.2014.007
Huang, 2012, Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy, Cancer, 118, 3123, 10.1002/cncr.26679
Müller, 2009, Harmonization of molecular monitoring of CML therapy in Europe, Leukemia, 23, 1957, 10.1038/leu.2009.168
Jabbour, 2014, Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management, Am J Hematol, 89, 547, 10.1002/ajh.23691
List, 2001, Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study, Blood, 98, 3212, 10.1182/blood.V98.12.3212
Fukushima, 2012, Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline, Anticancer Res, 32, 1347
Liu Yin, 2001, Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial, Br J Haematol, 113, 713, 10.1046/j.1365-2141.2001.02785.x
Ling, 2013, Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy, Br J Haematol, 160, 861, 10.1111/bjh.12178
Roumier, 2009, Pharmacogenomics in acute myeloid leukemia, Pharmacogenomics, 10, 1839, 10.2217/pgs.09.130
Boissel, 2002, Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy, Leukemia, 16, 1699, 10.1038/sj.leu.2402622
Boissel, 2005, Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype, Blood, 106, 3618, 10.1182/blood-2005-05-2174
Paschka, 2008, Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study, J Clin Oncol, 26, 4595, 10.1200/JCO.2007.15.2058
Whitman, 2008, DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication, Blood, 112, 2013, 10.1182/blood-2008-01-128595
Huang, 2007, Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years, Cancer, 110, 896, 10.1002/cncr.22850
Chen, 2010, An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China, J Hematol Oncol, 3, 21, 10.1186/1756-8722-3-21
Small, 1994, STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells, Proc Natl Acad Sci USA, 91, 459, 10.1073/pnas.91.2.459
Kiyoi, 1997, Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho), Leukemia, 11, 1447, 10.1038/sj.leu.2400756
Thiede, 2002, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, Blood, 99, 4326, 10.1182/blood.V99.12.4326
Chang, 2003, Simplified capillary electrophoresis detection of the Flt-3 internal tandem duplications and D835 point mutations in acute myeloid leukemia, Haematologica, 88, ELT04
Kottaridis, 2002, Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors, Blood, 100, 2393, 10.1182/blood-2002-02-0420
Assem, 2012, FLT3 internal tandem duplication and JAK2 V617F mutations in de novo acute myelogenous leukemia: relation with induction chemotherapy and overall survival, Life Sci J, 9, 1053
Döhner, 2005, Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood, 106, 3740, 10.1182/blood-2005-05-2164
Thiede, 2006, Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, 107, 4011, 10.1182/blood-2005-08-3167
Suzuki, 2005, Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia, Blood, 106, 2854, 10.1182/blood-2005-04-1733
Schlenk, 2008, Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia, N Engl J Med, 358, 1909, 10.1056/NEJMoa074306
Colovic, 2007, Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia, Ann Hematol, 86, 741, 10.1007/s00277-007-0325-3
Stirewalt, 2003, The role of FLT3 in haematopoietic malignancies, Nat Rev Cancer, 3, 650, 10.1038/nrc1169
Muñoz, 2003, Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication, Haematologica, 88, 637
Kiyoi, 1998, Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product, Leukemia, 12, 1333, 10.1038/sj.leu.2401130
Gregory, 2009, Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics, J Hematol Oncol, 2, 23, 10.1186/1756-8722-2-23
Liang, 2003, FLT3-TKD mutation in childhood acute myeloid leukemia, Leukemia, 17, 883, 10.1038/sj.leu.2402928
Lin, 2005, Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells, Clin Cancer Res, 11, 1372, 10.1158/1078-0432.CCR-04-1816
Chou, 2006, Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution, Cancer Res, 66, 3310, 10.1158/0008-5472.CAN-05-4316
Tang, 2009, AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations, Blood, 114, 5352, 10.1182/blood-2009-05-223784
Whitman, 2008, FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications, Blood, 111, 1552, 10.1182/blood-2007-08-107946
Sheikhha, 2003, Prognostic significance of FLT3 ITD and D835 mutations in AML patients, Hematol J, 4, 41, 10.1038/sj.thj.6200224
Whitman, 2007, FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study, J Clin Oncol, 25, 10532, 10.1200/jco.2007.25.18_suppl.10532